Neuroendocrine Tumor
Radioligand therapy extends PFS in neuroendocrine tumor subgroup
The addition of a radioligand therapy to first-line treatment with long-acting octreotide prolonged PFS for patients with gastroenteropancreatic neuroendocrine tumors, according to the agent’s manufacturer.
Most pituitary microadenomas do not change in size over 5 years of follow-up
Most adults with incident pituitary microadenomas have no change in size or a decrease in size during a median follow-up of nearly 5 years, according to findings published in Annals of Internal Medicine.
Healio | HemOnc Today announces new physician leadership
FDA rejects new drug application for surufatinib to treat advanced neuroendocrine tumors
The FDA has informed Hutchmed Ltd. that the data package included in a new drug application for surufatinib to treat pancreatic and extra-pancreatic neuroendocrine tumors does not support approval in the U.S., the company announced.
Addressing Gender Discrimination and Harassment in Medicine
Pamela Kunz, MD, is an expert in GI cancers and a courageous voice against gender discrimination and harassment in health care. In this episode, Kunz shares her story and provides guidance for those facing these types of challenges.
Nintedanib shows promise for nonpancreatic neuroendocrine tumors
Nintedanib appeared safe and effective for the treatment of advanced nonpancreatic neuroendocrine tumors, according to results of a phase 2 study published in Cancer.
Use ‘careful judgment’ to determine optimal neuroendocrine tumor management in COVID-19
Long-term treatment regimens for neuroendocrine neoplasms can be safely and temporarily delayed in the setting of life-threatening COVID-19-related symptoms, which should be “urgently treated,” according to new guidance.